Indoco Remedies Past Earnings Performance
Past criteria checks 1/6
Indoco Remedies has been growing earnings at an average annual rate of 29.6%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 12.9% per year. Indoco Remedies's return on equity is 8.7%, and it has net margins of 5.4%.
Key information
29.6%
Earnings growth rate
29.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.9% |
| Return on equity | 8.7% |
| Net Margin | 5.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
May 24
Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
Jan 26Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Jan 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Sep 16Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
May 21Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Aug 31Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Jul 04Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Jul 02Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Jun 10Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Mar 25Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price
Mar 09What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?
Feb 22Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?
Feb 07Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 17Is Indoco Remedies (NSE:INDOCO) A Risky Investment?
Dec 27
Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)
Dec 06What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?
Nov 14Investors Who Bought Indoco Remedies (NSE:INDOCO) Shares A Year Ago Are Now Up 66%
Oct 19These 4 Measures Indicate That Indoco Remedies (NSE:INDOCO) Is Using Debt Reasonably Well
Sep 14Indoco Remedies Limited (NSE:INDOCO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Aug 17How Much Did Indoco Remedies'(NSE:INDOCO) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jul 19Revenue & Expenses Breakdown
How Indoco Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 18,173 | 985 | 3,619 | 972 |
| 31 Dec 23 | 17,958 | 1,016 | 4,219 | 979 |
| 30 Sep 23 | 17,356 | 1,134 | 4,141 | 936 |
| 30 Jun 23 | 16,869 | 1,281 | 3,307 | 866 |
| 31 Mar 23 | 16,686 | 1,423 | 3,942 | 810 |
| 31 Dec 22 | 16,496 | 1,569 | 3,718 | 766 |
| 30 Sep 22 | 16,084 | 1,617 | 3,616 | 738 |
| 30 Jun 22 | 15,622 | 1,537 | 3,014 | 764 |
| 31 Mar 22 | 15,408 | 1,548 | 3,435 | 746 |
| 31 Dec 21 | 14,368 | 1,393 | 3,407 | 714 |
| 30 Sep 21 | 14,110 | 1,317 | 3,423 | 716 |
| 30 Jun 21 | 13,524 | 1,157 | 2,832 | 660 |
| 31 Mar 21 | 12,415 | 930 | 3,341 | 597 |
| 31 Dec 20 | 12,084 | 734 | 3,372 | 573 |
| 30 Sep 20 | 11,654 | 571 | 3,326 | 529 |
| 30 Jun 20 | 11,298 | 393 | 2,614 | 488 |
| 31 Mar 20 | 11,066 | 241 | 3,167 | 497 |
| 31 Dec 19 | 10,909 | 302 | 2,916 | 488 |
| 30 Sep 19 | 10,640 | 264 | 2,825 | 483 |
| 30 Jun 19 | 10,071 | 111 | 2,767 | 494 |
| 31 Mar 19 | 9,684 | -29 | 2,721 | 515 |
| 31 Mar 18 | 10,424 | 412 | 2,637 | 535 |
| 31 Mar 17 | 10,968 | 771 | 2,605 | 517 |
| 31 Mar 16 | 10,081 | 819 | 2,141 | 432 |
| 31 Mar 15 | 8,570 | 828 | 1,664 | 217 |
| 31 Mar 14 | 7,336 | 580 | 2,616 | 208 |
Quality Earnings: INDOCO has a high level of non-cash earnings.
Growing Profit Margin: INDOCO's current net profit margins (5.4%) are lower than last year (8.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INDOCO has become profitable over the past 5 years, growing earnings by 29.6% per year.
Accelerating Growth: INDOCO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INDOCO had negative earnings growth (-30.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18%).
Return on Equity
High ROE: INDOCO's Return on Equity (8.7%) is considered low.